journal article
Open Access
Sep 28, 2020
Clinical utility of Epstein‐Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma
Rong Tan
Sean Kean Ann Phua
Yoke Lim Soong
Lynette Lin Ean Oon
Kian Sing Chan
Sasidharan Swarnalatha Lucky
Jamie Mong
Min Han Tan
Chwee Ming Lim
Sean Kean Ann Phua
Yoke Lim Soong
Lynette Lin Ean Oon
Kian Sing Chan
Sasidharan Swarnalatha Lucky
Jamie Mong
Min Han Tan
Chwee Ming Lim
Cancer Communications
Vol. 40
No. 11
pp. 564-585
·
American Association for the Advancement of Science (AAAS)
Abstract
Abstract
Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor ubiquitously associated with the Epstein‐Barr virus (EBV), which is highly prevalent in South China, Southeast Asia, and North Africa. Despite being a highly radio‐sensitive and treatable cancer, a majority of NPC patients are diagnosed in their advanced stage, and locoregional and distant relapses following definitive treatment contribute largely to cancer‐specific mortality among these patients. Given that EBV‐driven NPC is the predominant variant seen in endemic regions, various EBV detection methods have been developed and are utilized in screening, prognostication, and post‐treatment surveillance of NPC patients. While the Immunoglobulin A (IgA) serology assay is the most extensively studied EBV detection method, the detection of plasma EBV DNA released during replication or cellular apoptosis has shown superior outcomes in endemic population screening, prognostication, and detection of distant relapse. Furthermore, there is emerging evidence on the use of circulating tumor cells, microRNAs, DNA hypermethylation, and combination assays in various clinical scenarios. Herein, this paper provides a comprehensive overview of the relevant studies using various EBV detection techniques in the management of NPC. Specifically, the recent advances, clinical evidence, and challenges associated with the clinical application of EBV liquid biopsies in population screening, prognostication, and surveillance of NPC are presented.
Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor ubiquitously associated with the Epstein‐Barr virus (EBV), which is highly prevalent in South China, Southeast Asia, and North Africa. Despite being a highly radio‐sensitive and treatable cancer, a majority of NPC patients are diagnosed in their advanced stage, and locoregional and distant relapses following definitive treatment contribute largely to cancer‐specific mortality among these patients. Given that EBV‐driven NPC is the predominant variant seen in endemic regions, various EBV detection methods have been developed and are utilized in screening, prognostication, and post‐treatment surveillance of NPC patients. While the Immunoglobulin A (IgA) serology assay is the most extensively studied EBV detection method, the detection of plasma EBV DNA released during replication or cellular apoptosis has shown superior outcomes in endemic population screening, prognostication, and detection of distant relapse. Furthermore, there is emerging evidence on the use of circulating tumor cells, microRNAs, DNA hypermethylation, and combination assays in various clinical scenarios. Herein, this paper provides a comprehensive overview of the relevant studies using various EBV detection techniques in the management of NPC. Specifically, the recent advances, clinical evidence, and challenges associated with the clinical application of EBV liquid biopsies in population screening, prognostication, and surveillance of NPC are presented.
Topics
No keywords indexed for this article. Browse by subject →
References
111
[1]
Cao S‐M, Simons MJ, Qian C‐N. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 2011;30((2)):114‐9.
10.5732/cjc.010.10377
[2]
Tsai S‐T, Jin Y‐T, Su I‐J. Expression of EBER1 in primary and metastatic nasopharyngeal carcinoma tissues using in situ hybridization: A correlation with WHO histologic subtypes. Cancer. 1996;77((2)):231‐6.
10.1002/(sici)1097-0142(19960115)77:2<231::aid-cncr2>3.0.co;2-p
[3]
Young LS, Dawson CW. Epstein‐Barr virus and nasopharyngeal carcinoma. Chin J Cancer. 2014;33((12)):581‐90.
[4]
Nakanishi Y, Wakisaka N, Kondo S, Endo K, Sugimoto H, Hatano M, et al. Progression of understanding for the role of Epstein‐Barr virus and management of nasopharyngeal carcinoma. Cancer Metastasis Rev. 2017;36((3)):435‐47.
10.1007/s10555-017-9693-x
[5]
Hadinoto V, Shapiro M, Greenough TC, Sullivan JL, Luzuriaga K, Thorley‐Lawson DA. On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood. 2008;111((3)):1420‐7.
10.1182/blood-2007-06-093278
[6]
Luzuriaga K, Sullivan JL. Infectious Mononucleosis. N Engl J Med. 2010;362((21)):1993‐2000.
10.1056/nejmcp1001116
[7]
Thorley‐Lawson DA. EBV Persistence–Introducing the Virus. Curr Top Microbiol Immunol. 2015;390((Pt 1)):151‐209.
[9]
Laichalk LL, Hochberg D, Babcock GJ, Freeman RB, Thorley‐Lawson DA. The Dispersal of Mucosal Memory B Cells: Evidence from Persistent EBV Infection. Immunity. 2002;16((5)):745‐54.
10.1016/s1074-7613(02)00318-7
[10]
Tsang CM, Deng W, Yip YL, Zeng M‐S, Lo KW, Tsao SW. Epstein‐Barr virus infection and persistence in nasopharyngeal epithelial cells. Chin J Cancer. 2014;33((11)):549‐55.
[11]
Hammerschmidt W. The Epigenetic Life Cycle of Epstein–Barr Virus. In: Münz C, editor. Epstein Barr Virus Volume 1: One Herpes Virus: Many Diseases. Cham: Springer International Publishing; 2015. p. 103‐17.
10.1007/978-3-319-22822-8_6
[12]
Tao Q, Young LS, Woodman CB, Murray PG. Epstein‐Barr virus (EBV) and its associated human cancers–genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci. 2006;11((2)):2672‐713.
10.2741/2000
[13]
Niedobitek G. Epstein‐Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Molecular Pathology : MP. 2000;53((5)):248‐54.
10.1136/mp.53.5.248
[14]
Tsao SW, Tsang CM, Lo KW. Epstein‐Barr virus infection and nasopharyngeal carcinoma. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 2017;372((1732)):20160270.
10.1098/rstb.2016.0270
[15]
Zeng Y, Jan MG, Zhang Q, Zhang LG, Li HY, Wu YC, et al. Serological mass survey for early detection of nasopharyngeal carcinoma in wuzhou city, china. Int J Cancer. 1982;29((2)):139‐41.
10.1002/ijc.2910290204
[16]
Deng H, Zeng Y, Lei Y, Zhao Z, Wang P, Li B, et al. Serological survey of nasopharyngeal carcinoma in 21 cities of south China. Chin Med J. 1995;108((4)):300‐3.
[17]
Liu Z, Ji M‐F, Huang Q‐H, Fang F, Liu Q, Jia W‐H, et al. Two Epstein‐Barr Virus–Related Serologic Antibody Tests in Nasopharyngeal Carcinoma Screening: Results From the Initial Phase of a Cluster Randomized Controlled Trial in Southern China. Am J Epidemiol. 2012;177((3)):242‐50.
10.1093/aje/kws404
[18]
Yu X, Ji M, Cheng W, Wu B, Du Y, Cao S. Assessment of the Long‐term Diagnostic Performance of a New Serological Screening Scheme in Large‐scale Nasopharyngeal Carcinoma Screening. J Cancer. 2018;9:2093‐7.
10.7150/jca.23755
[19]
[21]
Zheng X‐H, Lu L‐X, Cui C, Chen M‐Y, Li X‐Z, Jia W‐H. Epstein‐Barr virus mir‐bart1‐5p detection via nasopharyngeal brush sampling is effective for diagnosing nasopharyngeal carcinoma. Oncotarget. 2015;7((4)):4972‐80.
10.18632/oncotarget.6649
[23]
Wen Z, Li Z, Yong P, Liang D, Xie D, Chen H, et al. Detection and clinical significance of circulating tumor cells in patients with nasopharyngeal carcinoma. Oncol Lett. 2019;18((3)):2537‐47.
[24]
Yanjiao Mao WY, Jiangtian Chen, Qinghua Deng, Shixiu Wu. Cell counts and clinical significance of circulating tumor cells in patients diagnosed with nasopharyngeal carcinoma. Int J Clin Exp Med. 2019;12((7)):9167‐74.
[25]
Hui E, Li W, Ma B, Lam W, Chan K, Mo F, et al. Integrating post‐radiotherapy plasma Epstein‐Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. Ann Oncol. 2020.
10.1016/j.annonc.2020.03.289
[26]
Lv J, Chen Y, Zhou G, Qi Z, Tan KRL, Wang H, et al. Liquid biopsy tracking during sequential chemo‐radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nat Commun. 2019;10((1)):1‐10.
[27]
Wang W‐Y, Twu C‐W, Chen H‐H, Jan J‐S, Jiang R‐S, Chao JYC, et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res. 2010;16((3)):1016‐24.
10.1158/1078-0432.ccr-09-2796
[28]
Lo YMD, Chan LYS, Lo K‐W, Leung S‐F, Zhang J, Chan ATC, et al. Quantitative Analysis of Cell‐free Epstein‐Barr Virus DNA in Plasma of Patients with Nasopharyngeal Carcinoma. Cancer Res. 1999;59((6)):1188.
[29]
Chan KCA, Zhang J, Chan ATC, Lei KIK, Leung S‐F, Chan LYS, et al. Molecular Characterization of Circulating EBV DNA in the Plasma of Nasopharyngeal Carcinoma and Lymphoma Patients. Cancer Res. 2003;63((9)):2028.
[30]
[31]
Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch R‐D, et al. DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for Their Origin from Apoptotic and Necrotic Cells. Cancer Res. 2001;61((4)):1659.
[33]
Li Y, Sann KN, Chua M. The evolution of Epstein‐Barr virus detection in nasopharyngeal carcinoma. Cancer Biology and Medicine. 2018;15.
[34]
Kim KY, Le Q‐T, Yom SS, Pinsky BA, Bratman SV, Ng RHW, et al. Current State of PCR‐Based Epstein‐Barr Virus DNA Testing for Nasopharyngeal Cancer. J Natl Cancer Inst. 2017;109((4)).
[35]
Preiksaitis J, Pang X, Fox J, Fenton J, Caliendo A, Miller G, et al. Interlaboratory Comparison of Epstein‐Barr Virus Viral Load Assays. Am J Transplant. 2009;9:269‐79.
10.1111/j.1600-6143.2008.02514.x
[36]
Fryer JF, Heath A, Wilkinson DE, Minor PD. World Health Organization. Biologicals U, Standardization WHOECoB. Collaborative study to evaluate the proposed 1st WHO international standards for Epstein‐Barr Virus (EBV) for Nucleic Acid Amplification Technology (NAT)‐Based Assays / by Jacqueline F. Fryer, Alan B. Heath, Dianna E. Wilkinson, Philip D. Minor and the Collaborative Study Group. Geneva: World Health Organization; 2011.
[37]
Abeynayake J, Johnson R, Libiran P, Sahoo MK, Cao H, Bowen R, et al. Commutability of the Epstein‐Barr Virus WHO International Standard across Two Quantitative PCR Methods. J Clin Microbiol. 2014;52((10)):3802.
10.1128/jcm.01676-14
[38]
Vesper HW, Miller WG, Myers GL. Reference materials and commutability. The Clinical Biochemist Reviews. 2007;28((4)):139‐47.
[39]
Vo JH, Nei WL, Hu M, Phyo WM, Wang F, Fong KW, et al. Comparison of Circulating Tumour Cells and Circulating Cell‐Free Epstein‐Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy. Sci Rep. 2016;6((1)):13.
10.1038/s41598-016-0006-3
[40]
Lam WKJ, Jiang P, Chan KCA, Cheng SH, Zhang H, Peng W, et al. Sequencing‐based counting and size profiling of plasma Epstein–Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proc Natl Acad Sci. 2018;115((22)):E5115‐E24.
[41]
Lo S, Ho W‐K, Wei WI. Outcome of Patients With Positive Epstein‐Barr Virus Serologic Status in the Absence of Nasopharyngeal Carcinoma in Hong Kong. Arch Otolaryngol Head Neck Surg. 2004;130((6)):770‐2.
10.1001/archotol.130.6.770
[42]
Draborg A, Jørgensen J, Müller H, Nielsen C, Jacobsen S, Iversen L, et al. Epstein‐Barr virus early antigen diffuse (EBV‐EA/D)‐directed immunoglobulin A antibodies in systemic lupus erythematosus patients. Scand J Rheumatol. 2012;41:280‐9.
10.3109/03009742.2012.665944
[43]
Pickard A, Chen C‐J, Diehl SR, Liu M‐Y, Cheng Y‐J, Hsu W‐L, et al. Epstein‐Barr virus seroreactivity among unaffected individuals within high‐risk nasopharyngeal carcinoma families in Taiwan. Int J Cancer. 2004;111((1)):117‐23.
10.1002/ijc.20222
[45]
Wang M, Yu F, Wu W, Wang Y, Ding H, Qian L. Epstein‐Barr virus‐encoded microRNAs as regulators in host immune responses. International Journal of Biological Sciences. 2018;14:565‐76.
10.7150/ijbs.24562
[46]
Zhang G, Zong J, Lin S, Verhoeven RJA, Tong S, Chen Y, et al. Circulating Epstein–Barr virus microRNAs miR‐BART7 and miR‐BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment. Int J Cancer. 2015;136((5)):E301‐E12.
10.1002/ijc.29206
[47]
[49]
He Y, Zhang L, Cheng G, Yuan R, Zhuang Y, Zhang D, et al. Upregulation of circulating miR‐21 is associated with poor prognosis of nasopharyngeal carcinoma. International Journal of Clinical and Experimental Pathology. 2017;10:7362‐8.
Showing 50 of 111 references
Cited By
75
Diagnostic performance of EBV DNA load testing for nasopharyngeal carcinoma in nasopharyngeal swab outperforms the approach in other specimens
BMC Cancer
Xue-Qi Li, Dong-feng LIN · 2025
Advances in Nasopharyngeal Carcinoma Staging: from the 7th to the 9th Edition of the TNM System and Future Outlook
Current Oncology Reports
Binhao Wu, Caineng Cao · 2025
Molecular diagnosis of nasopharyngeal carcinoma: Past and future
Biomedical Journal
Cheng-Lung Hsu, Yu-Sun Chang · 2025
Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study
Cancer Cell
Jiawei Lv, Ling-Xin Xu · 2024
Metrics
75
Citations
111
References
Details
- Published
- Sep 28, 2020
- Vol/Issue
- 40(11)
- Pages
- 564-585
- License
- View
Authors
Cite This Article
Rong Tan, Sean Kean Ann Phua, Yoke Lim Soong, et al. (2020). Clinical utility of Epstein‐Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma. Cancer Communications, 40(11), 564-585. https://doi.org/10.1002/cac2.12100
Related
You May Also Like
Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?
Rui‐Mei Feng, Yi‐Nan Zong · 2019
1,051 citations
LncRNA‐mediated posttranslational modifications and reprogramming of energy metabolism in cancer
Yue‐Tao Tan, Jin‐Fei Lin · 2020
595 citations
A nomogram for predicting overall survival in patients with low‐grade endometrial stromal sarcoma: A population‐based analysis
Jie Wu, Huibo Zhang · 2020
460 citations